尊龙凯时-人生就是搏[中国区]网站

Huaota antibody drug discovery platform covers high-throughput automated hybridoma  technology, single B cell screening technology, nano antibody screening technology and antibody phage display technology. It supports rapid and large-scale screening of  therapeutic monoclonal antibodies.

The antibody drug discovery platform also covers antibody humanization, affinity maturation and Fc modification technologies for antibody optimization. Together with platforms of in vivo and in vitro drug efficacy evaluation and druggability analysis, it forms a complete drug discovery system.

The antibody drug discovery platform has served the development of a variety of new biologics in different therapeutic areas, which aims at providing affordable drugs to meet the unmet medical needs globally.

ispecific antibody (BsAb) targets two antigens or different epitopes at the same time, achieving synergistic effect of dual targets or enhancing broad-spectrum effects. It enhances anti-tumor immunity with increased binding specificity and synergy, while reducing off-target effects. Compared with traditional monoclonal antibody drugs or combination drugs, it has the advantages such as high efficacy and low cost.

Huaota has successfully created a variety of bispecific antibody R&D platforms, including receptor decoy fragment-antibody (Trap in Mab), Nanobody based, single-chain antibody, etc. Thanks to the excellent structure and style, the bispecific antibody platform has multiple advantages such as high purity, good production quality control, high yield, safety and effectiveness. At present, many products are in the international multi-center clinical research stages.

Huaota is identifying and developing innovative antibodies that target antigens which are highly expressed in tumors to build up the foundation of the ADC technology platform. In addition to high specificity, these antibodies aim to offer longer half-life and optimal affinity.  

Huaota aims to employ new classes of high specific and stable ADC linkers, which are designed to improve druggability and reduce potential toxicity.

Huaota aims to employ highly specific and potent small molecular payloads for the ADC technology platform, which can maintain activity in multidrug-resistant tumor cells and kill the tumor cells effectively.

Shanghai Huaota Biopharmaceutical Co., Ltd. has its own pilot production plant that meets applicable GMP requirements. The construction area of the bulk drug substance workshop is about 870m² with the clean rooms and controlled area of 727m² mainly including seeding room, fermentation room, purification room, ultrafiltration room, solution preparation room, and other auxiliary function rooms. The main equipment, such as disposable stirring system, single-use bioreactor, chromatography column, etc., are provided by international first-class equipment suppliers such as GE, PALL and Sartorius. The workshop can meet the needs of maximum 1000L cell culture scale.

The area of drug production workshop is 700m² with the clean rooms and controlled area of 578m², mainly including cleaning and sterilization room, unpacking room, filling room, liquid dispensing room, etc. The equipment includes pulsation vacuum sterilization cabinet, pre-filled syringe filling production line (Bosch system, production capacity of 17,000 pieces/hour) and vial filling production line (Bosch system, production capacity of 12,000 pieces/hour), etc.